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Purpose: To assess the effectiveness of alpha-1 adrenergic receptor blockers (α1-blockers) in the treatment of female lower 
urinary tract symptoms (LUTS).
Methods: A literature search was conducted using the PubMed/MEDLINE, Embase, and Cochrane Library databases. Four-
teen studies with 1,319 patients were ultimately included. The study comprised 2 analyses: a comparison of urinary symptom 
scores, maximal flow rate (Qmax), and postvoid residual (PVR) urine volume before and after α1-blocker administration in 8 
prospective, open-label studies and 5 randomized clinical trials (RCTs); and an evaluation of the same variables in α1-blocker 
and placebo groups in 4 RCTs. 
Results: The first meta-analysis showed that, following treatment, patients exhibited statistically significant symptom relief (mean 
difference [MD], -5.85; 95% confidence interval [CI], -7.71 to -3.99; P<0.00001), increased Qmax (MD, 3.67 mL/sec; 95% CI, 
2.76–4.59 mL/sec; P<0.00001), and decreased PVR volume (MD, -28.46 mL; 95% CI, -34.99 to -21.93 mL; P<0.00001). In the 
second meta-analysis, α1-blockers demonstrated significant symptom relief relative to placebo (MD, -1.60; 95% CI, -2.68 to 
-0.51; P=0.004). However, no significant differences were observed in Qmax (MD, 0.05 mL/sec; 95% CI, -0.74 to 0.83 mL/sec, 
P=0.91) and PVR (MD, -8.10 mL; 95% CI, -32.32 to 16.12 mL, P=0.51) between the α1-blocker and placebo groups.
Conclusions: These analyses suggest that α1-blockers are effective in the treatment of female LUTS patients. However, the ef-
fect of α1-blockers on female LUTS should be assessed according to the underlying cause, and the role of α1-blockers in com-
bination therapy with other drugs should also be investigated.
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• HIGHLIGHT
-  Alpha 1-blocker is effective in the treatment of female lower urinary tract symptoms. It showed significant symptom relief compared to pla-
cebo, however there was no differences in maximal flow rate and postvoid residual between the α1-blocker and placebo groups.
www.einj.org    57
 Kim, et al.  •  Alpha-1 Adrenergic Blockers in Women INJ
Int Neurourol J  March 31, 2019
INTRODUCTION
The European Urological Association guidelines suggest that, 
relative to placebo, alpha-1 adrenergic receptor blockers (α1-
blockers) reduce urinary symptoms and increase maximal flow 
rate (Qmax) in men with lower urinary tract symptoms (LUTS) 
[1]. These agents increase smooth muscle relaxation in the 
prostate and bladder neck. They constitute the first-line drug 
treatment of male LUTS due to their rapid onset of action, sat-
isfactory efficacy, and acceptable safety profiles. 
 Voiding dysfunction in women is defined by the Interna-
tional Continence Society and International Urogynecological 
Association as abnormally slow and/or incomplete urination 
diagnosed based on symptoms and urodynamic studies [2]. 
The overall prevalence of female voiding dysfunction is esti-
mated to be between 3% and 39% [3,4]. However, considering 
the present lack of standardized diagnostic criteria and clinical 
guidelines, female LUTS is likely overlooked and underestimat-
ed. Moreover, the pathophysiological mechanism of female 
LUTS remains unclear [5].
 Although not officially registered for the treatment of female 
LUTS [6], α1-blockers have been used to alleviate LUTS in 
women based on their presumed activity in the relief of func-
tional bladder outlet obstruction [7]. In part, the current use of 
α1-blockers for female LUTS is based on their remarkable ef-
fects in the treatment of male LUTS [8]. Published clinical trials 
evaluating the use of α1-blockers for female LUTS have re-
mained limited in prevalence and participation and have pro-
duced contradictory results. The lack of well-designed random-
ized clinical trials (RCTs) further limits meaningful conclu-
sions. Thus, the authors in the present study conducted a sys-
tematic review and meta-analysis assessing the effect of α1-
blockers on female LUTS to address some of the current con-
troversies and to obtain additional statistical information.
MATERIALS AND METHODS 
This systematic review was registered in PROSPERO (CRD42 
018096181). 
Search Strategy
The authors in the present study conducted computerized bib-
liographic searches of the PubMed/MEDLINE, Embase, and 
Cochrane Library databases up to April 2018. The search terms 
included “female or women,” “alpha blocker,” “lower urinary 
tract symptoms,” “overactive bladder,” “bladder outlet obstruc-
tion,” “urinary incontinence,” and relevant variants. Conference 
and meeting abstracts were excluded even if they otherwise met 
the eligibility criteria. The searches identified 482 candidate ar-
ticles. Two authors (DKK and YSH) independently reviewed 
the titles and abstracts based on the inclusion criteria and sub-
sequently reviewed the identified articles. 
Trial Inclusion Criteria and Exclusion Criteria
Following the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines, the eligibility of each 
study was evaluated using the PICOS (participants, interven-
tions, comparators, outcomes, and study design) method [9]. 
The authors in the present study defined the study population as 
female patients with a clinical diagnosis of LUTS and the inter-
vention as α1-blocker treatment. Where appropriate, the place-
bo was defined as the comparator. The following outcomes were 
analyzed: urinary symptom score (International Prostate Symp-
tom Score [IPSS] or American Urological Association Symptom 
Score [AUASS]), Qmax, and postvoid residual (PVR) urine vol-
ume. The inclusion criteria were: RCT or prospective design, 
nonanimal research, female patients with a clinical diagnosis of 
LUTS, use of α1-blockers, and reported values for IPSS or AU-
ASS scores, Qmax, and PVR urine volume. 
 The exclusion criteria were: retrospective design, the combi-
nation of α1-blockers with other drugs (e.g., anticholinergics or 
M-cholinolytics), and studies including only elderly women 
(mean age >70 years).
Data Extraction
Two authors (DKK and YSH) reviewed the full articles and ex-
tracted the data from each study independently. Any conflicts in 
the extracted data were resolved through consensus. The ex-
tracted data included study design details, inclusion and exclu-
sion criteria, randomization, participant demographics, treat-
ment characteristics (regimen, dosage, and duration), measured 
outcomes (IPSS or AUASS, Qmax, and PVR urine volume), and 
results (mean difference [MD] and standard deviation [SD]).
Assessment of Study Quality 
The design and implementation of RCTs were assessed for the 
risk of bias according to recent meta-analysis guidelines [10,11]. 
The risk of bias assessment included examination of the use of 
random sequence generation, allocation concealment, blinding 
of participants and researchers, blinding of outcome assess-
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ment, incomplete outcome data, and selective reporting. For 
prospective studies, the quality of the included clinical trials 
was evaluated according to the methodological index of the 
Downs and Black scale using 5 major assessment categories: re-
porting, external validity, bias, confounding, and power [12]. 
 The authors of the present study evaluated the certainty of 
comparisons using the Grading of Recommendations, Assess-
ments, Developments, and Evaluation (GRADE) system, which 
provides a systematic approach to the evaluation of the quality of 
evidence and strength of recommendations [10] through assess-
ments of the following criteria: methodology, precision, consis-
tency, directness, and risk of publication bias. Based on these cri-
teria, the authors in the present study assessed only direct evi-
dence of pairwise meta-analysis by classifying the quality of evi-
dence on a 4-level scale as high, moderate, low, and very low. 
Statistical Analysis
Changes in LUTS outcomes were measured by IPSS or AUASS, 
Qmax, and PVR urine volume values, which were recorded as 
continuous data. Mean and SD values were extracted from all 
studies except for that published by Lee et al. [5], which presented 
the results as median and interquartile range. The authors in the 
present study subsequently calculated the mean and SD values us-
ing a known statistical method [13,14]. Pooled MDs for pre- and 
posttreatment values and 95% confidence intervals (CIs) were cal-
culated for continuous variables. For RCTs, pooled MDs for treat-
ment and placebo group values were calculated along with 95% 
CIs. Adverse events were compared between α1-blocker and pla-
cebo groups using pooled odd ratios (ORs) for dichotomous data 
across studies. The meta-analyses were performed using the ran-
dom-effects model of DerSimonian and Laird to obtain pooled 
overall MDs with 95% CIs for outcomes [15].
 Statistical heterogeneity was assessed using the I2 value and 
the chi-square test. A Cochran Q statistic P<0.05 or I2 >50% 
indicated the presence of statistically significant heterogeneity. 
The authors in the present study assessed the stability of the re-
sults by sequentially excluding each included study as a sensi-
tivity analysis.
 Funnel plots and the Egger test were used to evaluate small-
study effects, with more than 10 studies included in the analy-
sis. A comprehensive meta-analysis was conducted to investi-
gate potential publication bias. The results are displayed using a 
funnel plot, with the study size shown on the y-axis as a func-
tion of the effect size on the x-axis. Symmetry reversal funnel 
Fig. 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analysis) flowchart. Chart presenting the flow of infor-
mation through the different phases of the systematic review, together with the utilized exclusion criteria.
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- Editorials, letters, reviews, and case reports, abstracts
- Not relevant to this review
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Records identified through database searching (n=482)
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diagrams did not show significant publication bias, which is in-
dicated by distortion and asymmetry of the inverted funnel 
plots. P-values<0.05 from the Egger test signaled statistically 
significant publication bias. 
 The meta-analysis was performed using Review Manager 
v.5.1 (The Nordic Cochrane Center, The Cochrane Collabora-
tion, Copenhagen, Denmark, 2008). All P-values were 2-sided, 
and, except for the test of discrepancy, P-values<0.05 were con-
sidered to indicate a statistically significant result.
 
RESULTS
Systematic Review Process
The authors in the present study used the PRISMA framework 
to analyze and summarize our systematic analysis and meta-re-
view process (Fig. 1). Only published studies were included to 
minimize publication bias. The initial database searches identi-
fied 482 articles, which were reduced to 406 following duplicate 
removal. Subsequently, title and abstract review eliminated 377 
articles, with only trials published in English included in the 
present study. An analysis of the remaining full-text articles 
with respect to the inclusion criteria resulted in the final selec-
tion of 14 studies (Table 1) with a total of 1,319 patients [5,6,16-
27]. Of these studies, 6 were RCTs and 8 were open-label pro-
spective studies. The α1-blockers used in these studies included 
alfuzosin, tamsulosin, and terazosin. The duration of treatment 
ranged from 4 to 12 weeks across all studies. In all publications, 
urinary symptom scores were assessed using the IPSS or AU-
Table 1. Characteristics of the selected studies   
Study Design No. of participants
Alpha-blocker dose 
(mg/day)
Treatment 
period
Comparator 
(mg/day)
Mean 
age (yr) Outcomes
Athanasopoulos, 
 2009 [16]
Open-label prospective 25 Alfuzosin 10 mg 8 Weeks None 53 Qmax, PVR
Chang, 2006 [17] Open-label prospective 71 Tamsulosin 0.2 mg 8 Weeks None 54.4 IPSS, Qmax, 
 PVR
Chang, 2008 [18] Open-label prospective 97 Tamsulosin 0.2 mg 6 Weeks None 63.8 IPSS, Qmax, 
 PVR
Costantini, 2009 [19] Open-label prospective 63 Tamsulosin 0.4 mg ≥4 Weeks None 60.2 Qmax, PVR
Hajebrahimi, 
 2011 [20]
RCT 40 Tamsulosin 0.4 mg 12 Weeks Prazosin 
 1–2 mg
Tamsulosin, 
 47.35; prazosin, 
 49.4
Qmax, PVR
Kim, 2011 [22] RCT 181 Tamsulosin 0.2 mg 12 Weeks Tamsulosin 
 0.2 mg + 
 tolterodine 
 2 mg
Tamsulosin, 52.2; 
 tamsulosin + 
 tolterodine, 53.7
IPSS, Qmax, 
 PVR
Kim, 2014 [21] Open-label prospective 296 Tamsulosin 0.2 mg 4 Weeks None 58.3 IPSS, Qmax, 
 PVR
Koh, 2011 [23] Open-label prospective 19 Alfuzocin 10 mg 12 Weeks None 50.4 IPSS, Qmax, 
 PVR
Lee, 2010 [24] Open-label prospective 106 Tamsulosin 0.2 mg 8 Weeks None 52.9 IPSS, Qmax, 
 PVR
Lee, 2018 [5] RCT 154 Alfuzosin 10 mg 8 Weeks Placebo Alfuzosin, 57.4; 
 placebo, 57.9
AUA-SS, 
 Qmax, PVR
Lepor, 1995 [25] RCT 29 Terazosin 10 mg 6 Weeks Placebo Terazosin, 60.6; 
 placebo, 62.8
AUA-SS, 
 Qmax
Low, 2008 [26] RCT 80 Terazosin 10 mg 14 Weeks Placebo NA IPSS, Qmax, 
 PVR
Pischedda, 2005 [27] Open-label prospective 18 Tamsulosin 0.4 mg 4 Weeks None 49.9 Qmax, PVR
Pummangura, 
 2007 [6]
RCT 140 Tamsulosin 0.2 mg 4 Weeks Placebo Tamsulosin, 42.5; 
 placebo, 49.8
IPSS, Qmax, 
 PVR
Qmax, maximal flow rate; PVR, postvoid residual volume; IPSS, International Prostate Symptom Score; AUASS, American Urological Association 
Symptom Score; NA, not available; RCT, randomized clinical trial.       
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Fig. 2. Forest plots comparing pre-post study outcomes (subgroup-analysis by study design). The evaluated outcomes included uri-
nary symptom score (A), maximal flow rate (B), and postvoid residual urine volume (C). P, prazosin; T, terazosin; SD, standard devia-
tion; CI, confidence interval; df, degrees of freedom.
A
B
C
Urinary symptom score
Maximal flow rate 
Postvoid residual urine
www.einj.org    61
 Kim, et al.  •  Alpha-1 Adrenergic Blockers in Women INJ
Int Neurourol J  March 31, 2019
ASS. These 2 questionnaires consist of the same 9 questions 
about incomplete emptying, frequency, intermittency, urgency, 
weak stream, straining, nocturia, and quality of life due to uri-
nary symptoms (Supplementary Figs. 1, 2).
 
Comparisons of Pretreatment and Posttreatment 
Outcomes 
Subgroup analyses were performed by study design and type of 
α1-blocker (Fig. 2, Supplementary Fig. 3).
Urinary symptom score
Urinary symptoms score was analyzed in 9 studies with 879 pa-
tients (Fig. 2A). Posttreatment outcomes demonstrated statisti-
cally significant symptom relief relative to pretreatment (MD, 
-5.85; 95% CI, -7.71 to -3.99, P<0.00001). Heterogeneity was 
observed among the included studies (I2 =89%; P<0.00001). 
Qmax
The analysis of Qmax comprised 13 studies with 1,003 patients 
(Fig. 2B). Qmax significantly increased following treatment 
(MD, 3.67 mL/sec; 95% CI, 2.76–4.59 mL/sec, P <0.00001). 
Heterogeneity among the included studies was observed 
(I2 =72%; P<0.0001). 
PVR volume
PVR volume was assessed on the basis of 12 studies with 938 
patients (Fig. 2C). Posttreatment PVR values significantly de-
creased relative to pretreatment values (MD, -28.46 mL; 95% 
Fig. 3. Forest plots comparing outcomes between α1-blocker and placebo groups. Evaluated outcomes included urinary symptom 
score (A), maximal flow rate (B), residual urine volume (C), and adverse events (D). SD, standard deviation; CI, confidence interval; 
df, degrees of freedom.
A
B
C
D
Urinary symptom score
Maximal flow rate 
Postvoid residual urine
Adverse event
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Fig. 4. Publication bias analysis. Funnel plots for maximal flow rate (A) and postvoid residual urine volume (B).
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Table 2. Downs and black scale for quality assessment of non-RCT and single-arm studies   
Study Reporting External validity
Internal validity
Power Total
Bias Confounding (selection bias) 
Athanasopoulos, 2009 [16] 7 1 3 1 1 13
Chang, 2006 [17] 7 1 4 1 2 15
Chang, 2008 [18] 7 1 3 1 2 14
Costantini, 2009 [19] 7 1 3 1 2 14
Kim, 2014 [21] 5 1 3 1 2 12
Koh, 2011 [23] 7 1 3 1 1 13
Lee, 2010 [24] 7 1 3 1 2 14
Pischedda, 2005 [27] 6 1 3 1 1 12
RCT, randomized clinical trial.      
CI, -34.99 to -21.93 mL; P<0.00001). Statistical heterogeneity 
was not observed (I2 =47%; P=0.04).
Outcome Comparisons Between Α1-Blocker and Placebo 
Groups
Urinary symptom score
Urinary symptoms score was analyzed in 4 studies with 396 pa-
tients (Fig. 3A). Statistically significant symptom relief was ob-
served following α1-blocker treatment relative to placebo (MD, 
-1.60; 95% CI, -2.68 to -0.51; P=0.004). Between-study hetero-
geneity was observed (I2 =68%; P=0.03).
Qmax
The analysis of Qmax comprised 4 studies with 396 patients 
(Fig. 3B). Treatment with α1-blockers did not significantly alter 
Qmax relative to placebo (MD, 0.05 mL/sec; 95% CI, -0.75 to 
0.83 mL/sec; P=0.91). Heterogeneity among the included stud-
ies was not observed (I2 =0%; P=0.50).
PVR volume
PVR volume was analyzed on the basis of 2 studies with 234 
patients (Fig. 3C). No significant difference in PVR volume was 
observed between the α1-blocker and placebo groups (MD, 
-8.10 mL; 95% CI, -32.32 to 16.12 mL; P=0.51). Between-study 
heterogeneity was observed (I2 =91%; P=0.001).
Adverse events
Adverse events were reported in 4 studies with 403 patients 
(Fig. 3D). No significant difference in adverse events was ob-
served between the α1-blocker and placebo groups (OR, 1.69; 
95% CI, 0.56-5.08, P=0.35). Between-study heterogeneity was 
observed (I2 =68%; P=0.02).
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Fig. 6. Study-specific bias risk. Risk of bias was assessed using 
the Cochrane Risk of Bias Tool. A green plus sign indicates a 
low risk of bias, a yellow question mark indicates an unclear risk 
of bias, and a red minus sign indicates a high risk of bias.
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Fig. 5. Risk of bias assessment graph. Risk of bias was assessed using the Cochrane Risk of Bias Tool.
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Sensitivity Analysis
A sensitivity analysis was performed using sequential exclusion 
of studies to evaluate the effect of each study on the overall re-
sults of the meta-analysis. The exclusion of any single study did 
not result in statistically significant changes in the results (data 
not shown). The results were statistically reliable.
Publication Bias, Quality Assessment, and Qualitative Risk 
of Bias
The funnel plot analysis of publication bias of the pre-post stud-
ies demonstrated a certain degree of symmetry (Fig. 4). The 
Egger test revealed no statistical evidence of publication bias in 
the meta-analysis of Qmax and PVR volume (P =0.77 and 
P=0.18, respectively).
 The Downs and Black scale was utilized to assess the quality 
of 8 prospective trials using the reporting, external validity, bias, 
confounding, and power assessment categories (Table 2). The 
Downs and Black scores of the evaluated studies ranged from 
12 to 15. The risk of bias graph and assessment of RCTs are 
summarized in Figs. 5 and 6. One study did demonstrate a sta-
tistically high risk of other biases (early stop due to low recruit-
ment and enrollment rate). 
 The results of the GRADE quality assessment for direct evi-
dence of each comparison are shown in Tables 3-5. Of the 10 
comparisons, certainty was moderate in 5 and low in 5. 
DISCUSSION
Large-population studies have indicated that LUTS are highly 
prevalent in women and men over 40 years of age [28]. Storage 
LUTS, including urinary incontinence, are more prevalent in 
women. Conversely, voiding LUTS are more common in men. 
However, women also suffer from voiding LUTS despite the 
absence of obvious anatomic obstructions, such as benign pros-
tatic obstructions seen in men. In men with benign prostatic 
hyperplasia, α1-blockers relieve LUTS via smooth muscle relax-
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ation in the prostate and the bladder neck. Thus, many clini-
cians have prescribed similar treatments to women with LUTS 
based on the assumption that α1-blockers will similarly affect 
the female bladder neck. Some open-label prospective trials 
[16-19,21,23,24,27] and RCTs [5,6,20,22,25,26] have examined 
the effect of α1-blockers on female voiding dysfunction. How-
ever, the outcomes of these studies have not been consistent. 
The lack of well-designed RCTs with large study populations 
further prevents the establishment of a consensus on the use of 
α1-blockers for LUTS in women. Therefore, the authors in the 
present study performed a systematic review and meta-analysis 
to assess the evidence and to provide more information regard-
ing the efficacy of α1-blockers in the treatment of female LUTS. 
 Our meta-analysis demonstrated that α1-blockers have ben-
eficial effects on female LUTS. Our study comprised 2 analyses: 
a comparison of urinary symptom scores and urodynamic pa-
rameters before and after α1-blocker treatment in 8 prospec-
tive, open-label studies and 5 RCTs, and the comparison of the 
same variables following α1-blocker and placebo treatments in 
4 RCTs. The first analysis indicated that α1-blockers are effec-
tive in reducing urinary symptom scores (-5.85 points), increas-
ing Qmax (+3.67 mL/sec), and decreasing PVR urine volume 
(-28.46 mL). Recent studies have suggested that α1-blockers 
may provide an effective treatment effect for female functional 
bladder outlet obstruction. Kumar et al. [29] reported that 50% 
of women with functional bladder outlet obstruction experi-
enced improvements in urinary symptoms, Qmax, and PVR 
after treatment with α1-blocker therapy alone. Yamanish et al. 
[30] also reported that female patients with detrusor underac-
tivity showed improvements in the total IPSS (-6.3 points) and 
PVR volume (48 mL) after 4 weeks of α1-blocker treatment, 
and that storage and voiding symptom scores were reduced.
 The second analysis demonstrated that α1-blockers are more 
effective in reducing urinary symptoms than placebo, but with 
an MD of only 1.6 points. Furthermore, no significant differ-
ences in Qmax and PVR volume between the α1-blocker and 
the placebo groups were observed. Zhang et al. [31] previously 
performed a meta-analysis comparing the effects of tamsulosin 
and various controls (placebo, anticholinergics, or combination 
therapy) in female LUTS patients. Our meta-analysis included 
studies using not only tamsulosin, but also other α1-blockers, 
such as alfuzosin and terazosin. In addition, only placebo con-
trol arms were included in our analysis. Furthermore, in con-
trast to Zhang and colleagues, the authors in the present study 
also added prospective open-label studies to compare pre- and 
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posttreatment clinical variables in our analysis of the effects of 
α1-blockers on female LUTS. 
 Although our meta-analysis indicated positive effects of α1-
blockers on both subjective and objective variables in the treat-
ment of LUTS, we recommend caution in the interpretation of 
the results. Bias is likely in simple pre-post comparisons in clin-
ical studies of voiding dysfunction. For example, as participants 
become accustomed to the test method (i.e., uroflowmetry), the 
results of the subsequent tests can improve. A strong behavioral 
factor has been observed in the placebo response of LUTS pa-
tients, as revealed by voiding diaries that make patients aware 
of their voiding habits, as well as of the timing and quantity of 
fluid intake [32]. In addition, significant placebo effects cannot 
be avoided in open-label studies. Thus, the clinical implications 
of our pre-post study meta-analysis are limited. 
 In contrast, the second meta-analysis, targeting placebo-con-
trolled RCTs, has more important clinical implications. This 
meta-analysis, which demonstrated a significant effect of α1-
blockers on urinary symptom relief, suggests that α1-blockers 
should be considered for the treatment of women suffering 
from LUTS. However, a <2-point MD in urinary symptom 
scores and an absence of significant differences in objective 
measurements were observed between the α1-blocker and pla-
cebo groups. These findings may be partly explained by the pla-
cebo effect. The involvement of neurotransmitters in the urina-
tion process can account for the LUTS placebo response, at 
least with respect to the subjective outcome. A placebo-induced 
dopamine release in LUTS patients has been hypothesized to 
improve bladder function [33]. Several studies have examined 
the specific factors influencing the placebo response in LUTS 
patients. Placebo therapy rapidly produces a significant im-
provement in Qmax and relieves the symptoms of benign pros-
tatic hyperplasia, with fading beneficial effects remaining even 
after 2 years [34]. Another study also suggested that the placebo 
effect is often rapid, but declines over time [35]. In the present 
meta-analysis, the treatment periods in the RCTs ranged from 
4 to 12 weeks. Thus, it is possible that the peak placebo effect 
was observed in the urinary symptom score and Qmax mea-
surements due to the short follow-up period. Nickel [34] also 
demonstrated that placebo responses were higher in patients 
with small or normal prostates. Assuming that female LUTS are 
more similar to LUTS in men with smaller prostates, a stronger 
placebo effect in women may further explain the observed lim-
ited effect of α1-blockers on female LUTS. 
 The authors in the present study compared adverse event 
rates between α1-blockers and placebo in the studies that re-
ported safety outcomes for the α1-blockers and found no statis-
tically significant difference in the adverse event rate of the α1-
blockers compared to placebo [5,6,25,26]. The side effects of 
α1-blockers reported in the studies were dizziness, headache, 
asthenia, GI discomfort, and edema. The most common ad-
verse events were dizziness and headache. Although the results 
of this study showed no difference in adverse events between 
α1-blockers and placebo, clinicians should always use caution 
regarding side effects while assessing a patient’s condition.
 Among the RCTs analyzed, Lee et al. [5] applied relatively 
strict inclusion criteria (AUASS ≥15 and Qmax <15 mL/sec 
and/or PVR volume >150 mL). However, the other 3 RCTs 
used very simple selection criteria (IPSS>8), with no specific 
cutoffs for Qmax or PVR volume [6,25,26]. Such broad criteria 
may not select for α1-blocker-responsive candidates. The meta-
analysis was further limited by the small sample sizes and the 
methodological quality of the included RCTs. Moreover, be-
tween-trial differences in α1-blockers and treatment periods 
also likely affected the results. Thus, high-quality RCTs, with 
large sample sizes, adequately defined study participants, and 
long-term treatment and follow-up, are required to overcome 
these limitations and to draw more reliable conclusions. 
 In conclusion, our results suggest that α1-blockers may be ef-
fective in the treatment of female LUTS. However, certain limi-
tations of the study, which could have led to inevitable bias, may 
have masked the effects of α1-blockers in the treatment of fe-
male LUTS. Thus, the results of this study should be interpreted 
with caution. Although α1-blockers are effective for treating fe-
male LUTS patients, the effect of α1-blockers on female LUTS 
should be assessed according to the underlying cause. In addi-
tion, the role of α1-blockers in combination therapy with other 
drugs should also be investigated.
 
SUPPLEMENTARY MATERIALS
Supplementary Figs. 1-3 can be found via https://doi.org/10. 
5213/inj.1836188.094.
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